Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

February 14, 2024

Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.

February 07, 2024

Identifying biomarkers and the mechanism of action of antibody-drug conjugates may optimize benefits with these agents in non–small cell lung cancer.

February 06, 2024

Andrew Brunner, MD, presents the profile of a 72-year-old man with MDS and the panel offers their initial impressions on the case, focusing on the treatment decisions.

February 06, 2024

Amy DeZern, MD, MHS, provides clinical insights on the first-line treatment of patients with lower-risk MDS and symptomatic anemia.

February 03, 2024

Benjamin Levy, MD, discusses the mechanism of action of antibody-drug conjugates in patients with non–small cell lung cancer.

January 30, 2024

Hematologist-oncologists discuss the risk stratification of patients with myelodysplastic syndromes and how patient risk status determines prognosis.

January 30, 2024

A panel of experts on myelodysplastic syndromes (MDS) introduce themselves and provide an overview of diagnosis practices, highlighting common symptoms and the typical patient presentation.

January 22, 2024

Dipti Patel-Donnelly, MD, discusses the management of high-risk hematologic malignancies in community practice.

January 03, 2024

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

December 27, 2023

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

December 27, 2023

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

December 20, 2023

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

December 20, 2023

The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.

December 18, 2023

Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial; updated outcomes with T-DM1 in those with residual invasive disease after neoadjuvant treatment and surgery; and more.

December 15, 2023

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

December 15, 2023

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

December 06, 2023

Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.

December 06, 2023

Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.

December 01, 2023

Benjamin Philip Levy, MD, discusses the evolution of antibody-drug conjugates in non-small cell lung cancer following updated data to be read out for this treatment population throughout 2023.

December 01, 2023

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.